12-week, multi-center, randomized, human body application test for the efficacy evaluation of rTG-Omega3 in dry eye disease accompanied by Meibomian Gland Dysfunction(MGD).

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008161

Enrollment

140

Registered

2023-02-03

Start date

2021-06-21

Completion date

Unknown

Last updated

2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Take rTG Omega-3 4C a day only as randomly assigned for experimental group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A person who has been diagnosed with Meibomian gland dysfunction (MGD) within 3 months(based on the latest surgery) of undergoing binocular cataract surgery(at least one of the three criteria below is satisfied). 1) During eyelid compression, the discharge of meibomian glands is reduced, showing cloudy, toothpaste-like secretions, or viscous secretions. 2) Two or more Telangiectasia on the edge of the eyelid. 3) Two or more Meibomian Glands Orfices are blocked *Drugs/treatment materials used during cataract surgery are subject to institutional standards. 2 Those with a Tearfilm Break-Up Time (TBUT) of less than 10 seconds 3. A person who agrees to participate in this human body application test before the human body application test begins and prepares a written consent form.

Exclusion criteria

Exclusion criteria: - Those who are judged to be inappropriate to participate in this human application test under the judgment of nvestigators

Design outcomes

Primary

Measure	Time frame
Tearfilm Break-up Time(TBUT)	—

Secondary

Measure	Time frame
Tear Volume(Strip Meniscometry Tube)	—

Countries

Korea, Republic of

Contacts

Public Contactjongseok song

Koera University Guro Hospital

crisim@korea.ac.kr+82-2-9494-1260

Outcome results